Monopar Therapeutics Q2 EPS $(0.17) Down From $(0.14) YoY

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.17) per share. This is a 21.43 percent decrease over losses of $(0.14) per share from the same period last year.

byBill Haddad

August 12, 2021

1 minute read

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.17) per share. This is a 21.43 percent decrease over losses of $(0.14) per share from the same period last year.

US, NATO Address The ‘Turkey Concern’ Over Finland, Sweden Seeking To Join The Military Alliance

By Navdeep Yadav

Today, 8:33 AM

North Atlantic Treaty Organization (NATO) and the United States expressed confidence that Turkey would not hold Finland and Sweden from joining the Western military alliance.

SPY

FOMC Minutes For Jan. 25-26 (Full Statement)

By Benzinga Newsdesk

Today, 8:33 AM

https://www.federalreserve.gov/newsevents/pressreleases/monetary20220126a.htm ndicators of economic activity and employment have continued to strengthen. The sectors most adversely affected by the pandemic have improved

SPY

News

Integral Ad Science Reports Launch Of Its New Brand Safety Solution For In-Feed Video Ads On TikTok

By Benzinga Newsdesk

Today, 8:33 AM

Integral Ad Science (NASDAQ:IAS), a global leader in digital media quality, today announced the launch of its new brand safety solution for in-feed video ads on TikTok. Using proprietary technology that IAS specifically

IAS

NLS Pharmaceutics Announces Interim Top-Line Data For Quilience In Patients With Narcolepsy; Co. Reports ‘Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline’

By Benzinga Newsdesk

Today, 8:33 AM

Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial Safety and

NLSP

Monopar Therapeutics Q2 EPS $(0.17) Down From $(0.14) YoY

Related Posts

US, NATO Address The ‘Turkey Concern’ Over Finland, Sweden Seeking To Join The Military Alliance

FOMC Minutes For Jan. 25-26 (Full Statement)

Integral Ad Science Reports Launch Of Its New Brand Safety Solution For In-Feed Video Ads On TikTok

NLS Pharmaceutics Announces Interim Top-Line Data For Quilience In Patients With Narcolepsy; Co. Reports ‘Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline’